Insilico Medicine Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 80
Employees
  • Latest Deal Type
  • Later Stage VC
  • Investors
  • 21

Insilico Medicine General Information

Description

Researcher and developer of drugs for longevity. The company utilizes innovative AI solutions for drug discovery and aging research as well as deep learning technology for drug re-purposing for aging and age-related diseases, allowing for the identification of molecules that may be effective against a variety of cancers as well as metabolic, cardiovascular and central nervous system diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • 307A, Core Building 1, 1 Science Park East Avenue
  • Hong Kong Science Park
  • Pak Shek Kok
  • Hong Kong

Insilico Medicine Timeline

2018201920202021
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Insilico Medicine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Jan-2020 000.00 00000 Completed Generating Revenue
6. Later Stage VC (Series B) 12-Aug-2019 0000 000.00 Completed Generating Revenue
5. Early Stage VC (Series A3) 18-Jun-2018 000 000.00 0000 Completed Generating Revenue
4. Early Stage VC (Series A2) 18-Jul-2017 000 000.00 Completed Generating Revenue
3. Early Stage VC (Series A1) 27-Feb-2017 00.00 000.00 Completed Generating Revenue
2. Early Stage VC 22-Feb-2017 $10M $11.5M Completed Generating Revenue
1. Seed Round 16-Apr-2014 $1.5M $1.5M 00.00 Completed Startup
To view Insilico Medicine’s complete valuation and funding history, request access »

Insilico Medicine Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 00.00 00.00 00 00.00 000
To view Insilico Medicine’s complete cap table history, request access »

Insilico Medicine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Researcher and developer of drugs for longevity. The company utilizes innovative AI solutions for drug discovery and agi
Drug Discovery
Pak Shek Kok, Hong Kong
80 As of 2020
000.00
0000 0000-00-00
0000000000 0 000.00

0000-000

pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit
0000 000000000
New Delhi, India
0000000000

00 00000

na aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea
0000 000000000
Guilford, CT
00 As of 0000
0000
000000000 - 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Insilico Medicine Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novo-Informatics Accelerator/Incubator Backed New Delhi, India 0000000000
00 000000000000 Venture Capital-Backed Guilford, CT 00 0000 000000000 - 0000
00000000 Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
00000 000000000000 Private Equity-Backed Newark, CA 00 00000 000000000000 00000
0000000000 Venture Capital-Backed Oxford, United Kingdom 000 00000 00000000000 00000
You’re viewing 5 of 15 competitors. Get the full list »

Insilico Medicine Executive Team (4)

Name Title Board Seat Contact Info
Alexander Zhavoronkov Ph.D Co-Founder, Chief Executive Officer & Board Member
Alexander Aliper President, EMEA
Qingsong Zhu Ph.D Chief Operating Officer & Secretary
Feng Ren Chief Science Officer
To view Insilico Medicine’s complete executive team members history, request access »

Insilico Medicine Board Members (3)

Name Representing Role Since
Alexander Zhavoronkov Ph.D Insilico Medicine Co-Founder, Chief Executive Officer & Board Member 000 0000
James Mellon Juvenescence Board Member 000 0000
Nisa Leung Qiming Venture Partners Board Member 000 0000
To view Insilico Medicine’s complete board members history, request access »

Insilico Medicine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Insilico Medicine Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Formic Ventures Venture Capital Minority 000 0000 000000 0
Harmonix Fund Venture Capital Minority 000 0000 000000 0
LongeVC Venture Capital Minority 000 0000 000000 0
Longevity Vision Fund Venture Capital Minority 000 0000 000000 0
Baidu Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 21 investors. Get the full list »

Insilico Medicine Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000.00 19-Jul-2018 00000 0000000 Other Healthcare Technology Systems 000000000 00000000000 00.0
Juvenescence AI 26-Jul-2017 Joint Venture Drug Discovery 000000000 00000000000 00.0
To view Insilico Medicine’s complete investments history, request access »